Endocrine Society's 96th Annual Meeting and Expo, June 21–
24, 2014 - Chicago
SAT-0567:
Assesment of Epicardial FAT Thickness in Subclinical
Hypothyroidism
Irmak Sayin
1,
Aycan Fahri Erkan
1,
Berkay Ekici
1,
Utku Kutuk
1,
Ahmet
Corakci
1and
Hasan Fehmi Tore
1 1
Ufuk University Medical Faculity, , Turkey
Presentation Number: SAT-0567
Date of Presentation: June 21, 2014
Abstract:Objective: Subclinical hypothyroidism, has multiple effects on the cardiovascular system. Epicardial
fat is a metabolically active organ and is clinically related with cardiovascular disorders and
atherosclerosis. Echocardiographic assessment of epicardial fat thickness (EFT) is a simple tool for cardiovascular risk stratification in clinical practice. In our study we aimed to assess the effects ofLevothyroxine (LT4) treatment on EFT thickness in patients with subclinical hypothyroidism (SCH).
Methods: The study included 22 patients with SCH and 16 healthy controls. Serum thyroid-stimulating
hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4) levels and EFT were determined in all subjects. Correlation analysis and linear regression analysis were performed for EFT thickness.
Results: Mean EFT was 4,1 and 6,05 mm in control and SCH subjects respectively. EFT of SCH
patients was high compared with control subjects at baseline (p<0.001). EFT did not changed
significantly after 3 months of follow-up period in control subjects; 4,1 to 4,3 mm respectively (p:0,142). But in SCH subjects; after LT4 treatment EFT reduced from 6,05 to 5,14 mm and this was statistically significant (p<0.001). Correlation analysis showed that EFT was significantly positively correlated with age, body mass index, thyroid-stimulating hormone and negatively correlated with fT4.
Conclusions: Epicardial fat thickness may be a useful indicator of cardiovascular risks in patients with
SCH and LT4 therapy may be an effective option in reducing these risks. Nothing to Disclose: IS, AFE, BE, UK, AC, HFT
